Taiwanese (TAIEX) Life Sciences Industry Analysis
- 7D-3.8%
- 3M-11.0%
- 1Y104.5%
- YTD-4.9%
Over the last 7 days, the Life Sciences industry has dropped 3.8%, driven by declines from every company within the industry. This takes the industry's 12 month performance to a gain of 105%.
Industry Valuation and Performance
Has the Taiwanese Life Sciences Industry valuation changed over the past few years?
| Date | Market Cap | Revenue | Earnings | PE |
|---|---|---|---|---|
| Wed, 26 Jan 2022 | NT$35.9b | NT$3.0b | -NT$120,147,000.00 | 34.6x |
| Fri, 24 Dec 2021 | NT$39.3b | NT$3.0b | -NT$120,147,000.00 | 37.2x |
| Sun, 21 Nov 2021 | NT$30.4b | NT$3.0b | -NT$120,147,000.00 | 35.9x |
| Tue, 19 Oct 2021 | NT$29.5b | NT$2.3b | -NT$631,150,000.00 | 31.2x |
| Thu, 16 Sep 2021 | NT$35.4b | NT$2.3b | -NT$631,150,000.00 | 32x |
| Sat, 14 Aug 2021 | NT$37.9b | NT$2.3b | -NT$631,150,000.00 | 32.1x |
| Wed, 09 Jun 2021 | NT$35.3b | NT$2.2b | -NT$810,177,000.00 | 28.4x |
| Tue, 02 Mar 2021 | NT$18.2b | NT$2.2b | -NT$912,568,000.00 | 22.2x |
| Fri, 04 Dec 2020 | NT$16.1b | NT$2.1b | -NT$914,668,000.00 | 22.5x |
| Mon, 07 Sep 2020 | NT$19.4b | NT$1.8b | -NT$1,161,248,000.00 | 19.4x |
| Sun, 31 May 2020 | NT$16.5b | NT$1.8b | -NT$951,923,500.00 | 20.9x |
| Wed, 04 Mar 2020 | NT$8.8b | NT$1.7b | -NT$771,818,000.00 | 18.4x |
| Sat, 07 Dec 2019 | NT$7.8b | NT$1.5b | -NT$580,833,000.00 | 18.4x |
| Tue, 10 Sep 2019 | NT$8.3b | NT$1.6b | -NT$347,403,000.00 | 15.1x |
| Mon, 03 Jun 2019 | NT$9.1b | NT$1.4b | -NT$298,437,500.00 | 22.1x |
| Thu, 07 Mar 2019 | NT$9.2b | NT$1.4b | -NT$240,203,000.00 | 27.2x |
21.5x
Current Industry PE: Investors are more optimistic on the industry, considering it's trading at a PE ratio of 34.6x which is higher than its 3-year average PE of 23.5x. It appears they are confident that earnings will grow faster in the future than they have historically.
Past Earnings Growth: The earnings for companies in the Life Sciences industry have improved over the last three years, and revenues for these companies have grown 30% per year. This means that more sales are being generated by these companies overall, and subsequently losses are decreasing too.
Industry Trends
Which industries have driven the changes within the Taiwanese Life Sciences industry?
| Clinical Research and Equipment | -3.80% | |
Industry PE: Investors are most optimistic about the Clinical Research and Equipment industry which is trading above its 3-year average PE ratio of 23.5x. This is likely because analysts are expecting annual earnings growth of 218%, which is higher than its past year's earnings growth of 19% per year.
Forecasted Growth: Analysts are most optimistic on the Clinical Research and Equipment industry, expecting annual earnings growth of 218% over the next 5 years. This is better than it's past earnings growth rate of 19% per year.
Top Stock Gainers and Losers
Which companies have driven the market over the last 7 days?
| Company | Last Price | 7D | 1Y | Valuation | |
|---|---|---|---|---|---|
| No data available | |||||